Home › Traumatic Brain Injury › NCT07131475

Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure

ReBlast Precision (Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure)

Who can join

Ages 18 to 50 · Men

Inclusion Criteria:

1. Active-duty Navy SEAL Service Member
2. Early career SEAL (0-2 years) or mid-late career SEAL (10-15 years)
3. Age 18-50 years
4. Males, regardless of race or ethnicity

Exclusion Criteria:

1. History of moderate or severe TBI
2. History of major neurological disorder
3. Untreated or unstable severe psychiatric condition
4. Current severe medical condition that requires long-term treatment
5. Any condition that may cause undue risk to the participant or create a logistical contraindication
6. MRI contraindication
7. PET contraindication

About the study

This is a 4-year, longitudinal study of 100 active-duty Navy SEALs. The goal of the study is to determine whether repeated blast exposure affects SEAL brain health and to develop an initial diagnostic testing protocol that detects repeated blast brain injury.

What is being tested

• PBR28 TSPO PET (drug)

Sponsor: Massachusetts General Hospital · Participants: 100 · Started: Oct 14, 2025

Contact the study team

• Brian L Edlow, M.D. · Phone: 617-724-6352
• Michael A Gordon, B.s. · Phone: 617-724-6352

Official record on ClinicalTrials.gov — NCT07131475

Locations in the U.S.

Conditions

• Traumatic Brain Injury

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.